New chair appointed at Wiltshire pharmaceutical firm

A new chair has been appointed at pharmaceutical firm Alliance Pharma.

The Wiltshire company say the key appointment is a sign that the business is shifting its focus onto new markets.

Alliance is evolving from a prescription medicines business to a fast growth consumer healthcare company.

Consumer healthcare revenues now make up 75 per cent of group revenues.

Over the last five years, Jo LeCouilliard has been instrumental in driving this transition, first as a Non-Executive Director and, more recently, as chair.

Under her leadership, the company has strengthened the board, appointing two new directors with consumer experience, particularly in the APAC region.

Jo and the board feel that it is now appropriate for her to step down and to appoint a new chair, with strong international consumer healthcare experience, to lead the company through its next strategic phase, focusing on organic growth through marketing and innovation.

Camillo Pane will be appointed to the role of chair following a handover period from Jo.

Camillo has over thirty years’ experience in US, European and Asian public, multinational consumer companies.

He has held a number of senior positions at Reckitt Benckiser where he spent almost 20 years across both global and regional roles, including senior vice president and global category officer for consumer health.

He moved to Coty Inc, one of the largest beauty companies in the world, where, as CEO, he led the merger with Procter & Gamble Specialty Beauty.

Most recently, he was group CEO of Health & Happiness Group, a global Health and Nutrition company listed on the Hong Kong Stock Exchange with revenues of around $2bn.

Richard Jones, senior independent director of Alliance, said: “On behalf of the Alliance Board and the Company I would like to thank Jo for her significant contribution to Alliance over the past five years and wish her well for the future.

“We look forward to Camillo joining the board as chair and harnessing his wide-ranging consumer healthcare experience to further enhance and develop our group strategy.

“In the meantime, the board remains focused on creating value for our shareholders by investing in growth whilst carefully managing our cost base.”